Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 13, 2024JAMA

The State of State Biomarker Testing Insurance Coverage Laws

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGrace A. LinJCJanet M. CoffmanKPKathryn A. Phillips

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lin et al. (2024) studied this question.

synapsesocial.com/papers/68e6a4f8b6db643587628243https://doi.org/10.1001/jama.2024.6058
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 20182019 · 581 citations
  2. 2Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non–Small Cell Lung Cancer and Colorectal Cancer2023 · 37 citations
  3. 3The Effects of Federal Parity on Mental Health Services Use and Spending: Evidence From the Medical Expenditure Panel Survey2019 · 9 citations
  4. 4Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States2022 · 77 citations
  5. 5Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality2014 · 69 citations